Stay updated on Dara-VCd vs VTd, Maintenance with IXA Clinical Trial
Sign up to get notified when there's something new on the Dara-VCd vs VTd, Maintenance with IXA Clinical Trial page.

Latest updates to the Dara-VCd vs VTd, Maintenance with IXA Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision tag was updated to v3.6.4, indicating a software update to the study page. The update does not modify the study content or visible information.SummaryDifference0.0%

- Check20 days agoChange DetectedExpanded the study's recruitment footprint by adding 24 sites across Italy, Greece, Czechia, and other countries, reflecting a multi-site design. The sponsor organization name was updated from Stichting European Myeloma Network to European Myeloma Network B.V., with the related location listings adjusted accordingly.SummaryDifference3%

- Check28 days agoChange DetectedThe page no longer displays the disease label 'Multiple myeloma' and removes the 'related topics' section, including the 'MedlinePlus Genetics' link. This reduces the visible context and access to a genetics resource on the study record.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, reflecting a new version of the study record. This indicates a new version of the page but does not change study data or user-facing content.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now lists 'Multiple myeloma' as a keyword and adds related topics such as 'MedlinePlus Genetics'. The revision history shows an update to version v3.6.2, replacing v3.6.0.SummaryDifference0.2%

- Check49 days agoChange DetectedThe Related Topics header and two related topic items, including 'Multiple myeloma' and 'MedlinePlus Genetics', were removed.SummaryDifference0.2%

Stay in the know with updates to Dara-VCd vs VTd, Maintenance with IXA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dara-VCd vs VTd, Maintenance with IXA Clinical Trial page.